The role of antimicrobials in management of periodontal diseases
Firdaus, Bilawal Aziz; Sharma, Praveen; Milward, Michael

DOI:
10.12968/denu.2019.46.10.952

License:
None: All rights reserved

Document Version
Peer reviewed version

Citation for published version (Harvard):
Title: The role of antimicrobials in management of periodontal diseases

Author’s Name, degrees and affiliations:

Mr Bilawal Firdaus

Dr Praveen Sharma, PhD, FHEA, MJDF (RCS Eng.), BDS
Clinical Lecturer in Restorative Dentistry
University of Birmingham School of Dentistry
Birmingham, UK.

Prof Michael Milward, PhD, FHEA, MFGDP (London), MFDS RCPS (Glasgow), BDS, GDC Specialist in Periodontology
Consultant in Periodontology
University of Birmingham School of Dentistry
Birmingham, UK.
Title: The role of antimicrobials in management of periodontal diseases

Abstract: With the looming threat posed by antimicrobial resistance, appropriate prescribing of antimicrobials, including antibiotics, is increasingly relevant. In this article, we will explore the reasons why antimicrobial therapy is not the mainstay of treatment for most patients with periodontitis. We will explore some specific exceptions to this rule, including why such exceptions exist. In addition, we will present protocols for periodontal and antimicrobial therapy to maximise the treatment response when adjuvant antimicrobials are used.

Clinical relevance statement: This manuscript highlights the need for appropriate prescribing within dentistry as a whole and specifically when it comes to the management of periodontal diseases, where antimicrobials do not form the mainstay of treatment, with some exceptions.

Objective statement: The reader should appreciate the importance of appropriate prescribing of antimicrobials in the context of management of periodontitis. The reader should be aware of situations in which prescribing of antimicrobials is advocated as well as clinical and microbial protocols to follow in such situations.
Introduction:

Given that periodontitis, on a basic level, is an imbalance between the microbial load and the host-response to that microbial load, at first glance it may appear that antimicrobials, specifically antibiotics, should be the mainstay of treating periodontitis, however this is not the case. Before we discuss this further it is useful to clarify some terminology, an antimicrobial is a substance capable of killing or inhibiting the growth of any micro-organism whereas an antibiotic is a substance capable of killing or inhibiting the growth of bacteria specifically. The mainstay of managing periodontitis is not via the use of antibiotics. It is rather via the lowering the bacterial load, as discussed in other papers in this issue, by mechanical removal (brushing and interdental cleaning). This can be aided by the removal of plaque retentive factors (PRFs) by a dental care provider along with bearing the periodontium in mind when dentally rehabilitating the patient by providing restorations that designed to minimise plaque retention and are cleansable by the patient. In this paper, we will discuss

- Reasons why antibiotics are not routinely indicated in the treatment of periodontitis
- Reasons for using antibiotics sparingly
- Exceptional circumstances in which antibiotics may be indicated in the management of periodontitis
- Types of antibiotics (local/systemic)

Reasons why antibiotics are not routinely indicated in the treatment of periodontitis

Site of periodontitis

In periodontitis, the bacteria are mainly contained in the biofilm present on the tooth/root surface. This site is effectively external to the body and the defence mechanisms therein. The challenge of
this external infection is compounded by the fact that the bacteria are present in a biofilm, as opposed to floating around planktonically,

Figure 2 shows a probe inserted into a mesio-buccal pocket with suppuration evident. Consider the environment that the probe is in. Is it “inside” or “internal” to the body? Or can it be thought of as being on the “surface” of the body? Bacteria that exist in this environment, exist in a biofilm on the surface of the tooth and plankonically in the exudate from the pocket.
Treating this suppuration with antibiotics alone would be challenging as biofilms are notoriously resistant to penetration by antibiotics (Marsh, Moter et al. 2011). Therefore, disrupting this biofilm, by mechanical instrumentation, would greatly increase the efficacy of any antibiotic used in as an adjunct in the management of periodontitis see Figure 2.

Figure 2
Diagram to represent the biofilm present on the root surface (A) and how instrumentation disrupts the biofilm to produce a single cell planktonic bacterial suspension (B). The bacteria are represented by blue cocci and red bacilli, and antibiotics by yellow arrows. It can be seen in A that the antibiotic struggles to penetrate the biofilm and has the ability to act on a small surface area of the bacterial surface whereas when the biofilm is disrupted by instrumentation the antibiotic can easily access the bacterial cell surface resulting in enhanced efficacy.

All systemic medications need to be initially absorbed by the gastro-intestinal tract and then pass through the liver, before being available in the blood stream, this can limit the systemic concentration. In addition, for an antibiotic to reach the gingival crevicular environment it needs to be able to pass through the gingival tissues and be present in the gingival crevicular fluid (GCF).
before it can act in the periodontal pocket. This limits the effective dose reaching the gingival crevicular environment, as well as the time that the antibiotic remains in this environment, both of which further limit the effectiveness of antibiotics in these sites.

Non-specific bacteria involved in periodontitis

Unlike some diseases, periodontitis does not have one causal organism implicated in its pathogenesis. Not only this, there are many types of bacteria implicated in the pathogenesis of periodontitis. These are predominately anaerobic, i.e. bacteria that have a preference of an oxygen depleted environment which is found in the periodontal pocket. Bacteria are also be classified on the basis of Gram staining which is where certain bacteria, with a cell wall with a thick peptidoglycan layer, stain up blue in the presence of a dye. These are termed Gram positive bacteria. Other bacteria, whose cell wall does not have a thick peptidoglycan layer, do not get stained blue and are termed Gram negative. Periodontitis is most commonly associated with Gram negative bacterial types. It would be ideal to have an antibiotic that just specifically targets these periodontal pathogens but such an antibiotic is not available and the antibiotics we do use will have a wider systemic effect e.g. impact on the gastrointestinal tract flora. One of the potential serious consequences is overgrowth of the bacterium Clostridium difficile, leading to diarrhoea. Another issue with the use of non-specific or broad-spectrum antibiotics is the potential emergence of resistance, which will be discussed later in this article.

Patient compliance

The predominant method of reducing bacterial plaque levels is by instigating patient based tailored oral hygiene methods. Dental care professionals can aid this by the removal of PRFs including calculus and overhanging restoration/s., as well as always designing restorations or removable partial dentures that minimise plaque retention. One of the key reasons for the ineffectiveness of general systemic antibiotic use is patient compliance in regard to frequency of use and taking a full
course of antibiotics as prescribed. Deviation from the prescribed course of antibiotics will lead to a reduction in their effectiveness.

In summary, the site of the infection in periodontitis being on the “surface” of the body, the bacteria being in a biofilm, the sheer variety of bacteria involved with periodontitis, doubts about patient compliance and that non-surgical periodontal in most cases produces good outcomes all conspire against the use of antibiotics in most cases of periodontitis.

**Reasons for using antibiotics sparingly**

In addition to the reason discussed above for limiting the use of antibiotics in periodontal disease management, and additional reason relates to antibiotics resistance. This is a major healthcare concern with England’s Chief Medical Officer stating that ‘The world is facing an antibiotic apocalypse.” Unless action is taken to halt the practices that have allowed antimicrobial resistance to spread and ways are found to develop new types of antibiotics, we could return to the days when routine operations, simple wounds or straightforward infections could pose real threats to life.

This opinion is echoed across the healthcare community. So we need to play our part and ensure that antibiotics are only used in specific and limited situations. This relates to periodontal disease management as well as inappropriate use of antibiotics in dentistry as a whole. The use of antibiotics leads to the development of resistant strains of bacteria. These strains are often termed “super-bugs” in the media.. There is an evolutionary pressure for bacteria to resist the antibiotics designed to kill them or inhibit their growth. This can be illustrated via a sobering video by Harvard Medical School [https://www.youtube.com/watch?v=pIvk4NVIUh8]. This video highlights the natural evolution of bacterial resistance and the fact that this is accelerated by the evolutionary pressure exerted by the use of antibiotics. Added to this is the lack of development in the field of
antibiotics, with the last new class of antibiotics developed in the mid-1980s, leading to a “discovery void” since then. (Silver 2011).

The growing antibiotic resistance, coupled with a lack of development of new antibiotics, means that in the future, infections that we commonly treat with antibiotics will become harder and harder to treat. The responsibility for the appropriate prescription of antibiotics lies with the prescriber but the greater threat of antibiotic resistance needs tacking on a few fronts, including the miss-use of antibiotics in the farming and agriculture (Venter, Henningsen et al. 2017).

**Types of antibiotics**

Antibiotics have two modes of action, they can either be bactericidal, in which case they kill or lyse bacteria or they can be bacteriostatic, in which case they prevent bacterial multiplication thereby allowing the hosts inflammatory response to remove bacteria. The bacteriostatic or bactericidal
actions may be achieved in a wide variety of ways. These include inhibiting the bacterial cell from synthesizing essential components such as cell walls or proteins or nucleic acids.

In addition, antibiotics can be classified as systemic or local delivery with the former affecting the whole body, as well as the site of need and the latter having a limited effect on the rest of the body, apart from the site of need/delivery. The advantages and disadvantages of local delivery systems, compared to systemic antibiotics, are summarised in the table below (Table 1).

**Table 1: Advantages and disadvantages of local delivery systems, compared with systemic delivery of antimicrobials.**

<table>
<thead>
<tr>
<th>ADVANTAGES</th>
<th>DISADVANTAGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduced systemic dose</td>
<td>Expensive</td>
</tr>
<tr>
<td>High local concentration</td>
<td>Still require RSD or biofilm disruption</td>
</tr>
<tr>
<td>Superinfections, such as with Clostridium difficile, unlikely</td>
<td>Limited indications</td>
</tr>
<tr>
<td>Drug interactions unlikely</td>
<td></td>
</tr>
<tr>
<td>Site specific</td>
<td></td>
</tr>
<tr>
<td>Patient compliance not an issue as applied by healthcare provider</td>
<td></td>
</tr>
<tr>
<td>Can utilise agents which can’t be utilised systemically, e.g. chlorhexidine</td>
<td></td>
</tr>
</tbody>
</table>
In the next section, we shall discuss systemic and local delivery of antimicrobials, in the management of periodontitis.

**Indications for the use of systemic antibiotics in periodontitis**

There are a few exceptions to the general rule of not prescribing antibiotics in the management of periodontitis. These include:

The disease formally known as “Aggressive periodontitis”

The new classification of periodontitis, discussed in this issue, has removed the term “aggressive periodontitis”. This is because it is now thought to be a variant of periodontitis, as opposed to a unique identity in itself. The cases which would have been captured as aggressive periodontitis are now captured either as periodontitis with a molar-incisor pattern or periodontitis of grade C or even grade B. However, these categories also capture cases of periodontal disease which we would not traditionally have been classified as aggressive periodontitis. For example a 70 year old patient with >70% bone loss in the worst site would be grade C but would not have previously be thought of as “aggressive periodontitis”. Similarly, a 35 year old with 1/3rd bone loss at the worst site would currently be grade B, but previously may have been considered a case of aggressive periodontitis. The distinguishing feature would still be bone loss not in keeping with the patient’s level of oral care and/or absence other risk factors and the rapidly progressive nature of disease. In this respect, there is clarification needed between the old and new classification, which is particularly relevant in cases previously thought of as aggressive, because these had a specific management protocol which included the use of systemic antibiotics and currently this has not been fully elucidated in the new classification. This was because, it was believed that in aggressive disease, in addition to being present in a biofilm on the tooth surface, bacteria were also able to invade the local soft tissue and act as a reservoir there. Hence, biofilm disruption by means of root surface debridement (RSD) alone
would be ineffective in removing this reservoir. For this reason, antibiotics are recommended in such cases using the following protocol:

Instigate oral hygiene measures, complete RSD of all sites indicated by DPC in a short a time as possible, ideally, within one week. Immediately following the completion of the last visit of RSD, and the ensuing disruption of biofilm, the patient is to start amoxicillin 500mg and metronidazole 400mg TDS for 7 days. Patients need to be cautioned regarding alcohol intake while taking metronidazole. Similarly, care must be taken with the patient’s existing medication when prescribing antibiotics, for example patients on warfarin may find their INR raised as there is an increased the anti-coagulant effect of warfarin. Metronidazole is best avoided in such patients, but if it is used liaison with the anticoagulant clinic with close INR monitoring will be required. Cases of amoxicillin interacting with warfarin are rare. In cases where the amoxicillin and metronidazole regime cannot be prescribed, such as in patients allergic to penicillin or patients on warfarin, the antibiotic of choice is doxycycline which is prescribed as a 21-day course of 100mg, once a day with a “loading dose” of 200mg on the first day. Like all tetracyclines, the use of doxycycline should be avoided in patients who are pregnant or breastfeeding due to the risk of deposition of the drug in developing bones and teeth leading to discoloration (tetracycline staining). As with all antibiotics, it is important to stress that patients take these as prescribed and finish the course of antibiotics. An alternative new regime to doxycycline, without the shortcomings of loss of compliance with a 21 day course of antibiotics as well as contraindications in pregnant/breastfeeding patients, is Azithromycin prescribed 500mg doses once a day for three days. Patients may comply better with this short course antibiotic and the drug is thought to be retained in the tissues for a period of time such that a missed dose may be compensated by continuing the drug on the following day. Azithromycin has been shown to be beneficial especially in deeper sites of more rapidly progressing (grade C) periodontitis.

*Necrotising Periodontal Diseases (NPDs)*
The new classification of periodontitis categorises necrotising periodontitis and necrotising gingivitis together as NPDs. Patients with NPDs typically have pain associated with the condition, which is unlike most cases of periodontal disease, and typically present with sloughing of the interdental papillae and characteristic halitosis. In such cases, antimicrobials are also indicated due to the relatively narrow range of bacteria involved in these disease processes (anaerobic spirochetes and fusiform bacteria). For this particular form of periodontal disease, metronidazole is the drug of choice as it is particularly effective against anaerobic bacteria. Patients should receive a course of 400mg of metronidazole, TDS for 3 days. The cautions regarding the use of metronidazole in the precious section also apply here. In the management of NPDs, risk factors such as smoking and stress should be managed and antibiotics may need to be prescribed prior to non-surgical debridement as the gingivae may be too painful to debride.

It goes without saying that the hesitance in prescribing antibiotics should be balanced with the immediate, medical needs of the patient. As such, signs of spreading infections such as lymphadenopathy, swellings which may compromise the airway or approaching the infra-orbital areas or pyrexia may still warrant the use of systemic antibiotics, even if such infections are periodontal in origin.

**Indications for the use of local antimicrobials in periodontitis**

The use of local antimicrobials allows for the targeted deposition of a higher dose of antimicrobials, in a sustained fashion, at the site of the disease to the gingival crevice, thereby limiting the systemic dose of the antimicrobial agent. This also limits potential side effect and drug interactions.

Local antimicrobials are only indicated for the odd site that does not respond to conventional, non-surgical RSD in a patient with well controlled risk factors including good oral hygiene and no detectable subgingival calculus deposits. They should not be used as the first line of therapy, in the
absence of non-surgical therapy, in patients with poor oral hygiene, on multiple sites, or to treat endo-perio lesions. Prior to prescribing local antimicrobials, the reasons for failure of conventional RSD to resolve pocketing should be investigated. These are mentioned in more detail in the paper on “Periodontal Maintenance” in this issue. Common reasons for non-response to initial periodontal therapy include incomplete removal of subgingival deposits, poor oral hygiene on the part of the patient, lack of addressing of risk factors such as smoking cessation, and perio endo lesions, which will not respond to periodontal therapy alone. If a patient does not have these reasons for non-responsiveness, other strategies such as periodontal surgery or use of local/systemic antimicrobials may be considered.

Whilst surgical treatment is an option, local delivery systems may be a suitable first option as it is less invasive in nature and doesn’t require the specialist skills needed for surgical management. A systematic review on the effects of local antimicrobials (Matesanz-Perez, Garcia-Gargallo et al. 2013) as adjuncts to subgingival debridement in treating chronic periodontitis looked at 56 papers and came to the conclusion that the use of local antimicrobials is worthwhile in deep or recurrent sites and that those with sustained release properties (that have a mechanism to ensure the antimicrobial agent is retained in the pocket for longer) produce better results.

Commonly used local delivery systems for the management of periodontitis include PerioChip and Chlosite, which contain the antimicrobial agent chlorhexidine, Dentomycin and Attridox which contain the antibiotic tetracycline and Elyzol which contains the antibiotic metronidazole. It is beyond the scope of this paper to discuss these in detail and practitioners are recommended to ensure adequate training before utilizing these systems. A comprehensive review by Jepsen & Jepsen in 2016 offers a useful insight into their use(Jepsen and Jepsen 2016).

**Alternative therapies**
There are two further therapy modalities used in the management of periodontitis which will be considered in this article:

**Periostat**

This consists of 20mg of doxycycline, given twice a day for 3 months, systemically, as an adjunct to supra-/sub-gingival instrumentation. This low dose of doxycycline is considered to be sub-antimicrobial meaning that the dose is insufficient to inhibit the growth of bacteria, rather it is prescribed for its role as a collagenase inhibitor. Collagenase, an enzyme produced by both bacterial and human cells, is responsible for the breakdown of collagen and is implicated in periodontal breakdown; therefore blocking this enzyme may have efficacy in the management of periodontitis.

A review by Preshaw et al (Preshaw, Hefti et al. 2004) highlighted that Periostat, when used as an adjust to periodontal therapy (scaling and root planning/SRP) yielded clinically and statistically significant reductions in probing depths and gains in clinical attachment levels compared with those seem with scaling SRP alone. The authors also concluded that using a sub-antimicrobial dose of doxycycline was unlikely to exert a significant evolutionary pressure and therefore less likely to accelerate the development of drug resistant bacteria.

**PerioWave**

This is an example of an antimicrobial photodynamic therapy (aPDT) which utilises a photoactive agent that absorbs light of a specific wavelength and is able to be taken up preferentially by bacteria. When the agent is exposed to this specific wavelength of light, free radicals are produced that are cytotoxic to microorganisms and their products (Sgolastra, Petrucci et al. 2013). Systematic review and meta-analysis of aPDT shows limited data but the data available shows a mean pocket depth improvement of 0.19mm and mean clinical attachment gain of 0.37mm. This review/analysis came to the conclusion that aPDT produces short term benefits over conventional therapy and the
evidence for medium/long term benefits is insufficient and further studies are required (Sgolastra, Petrucci et al. 2013).

The alternative therapies indicated offer new and interesting ways of managing periodontitis but are currently not used in mainstream management of periodontitis. Conventional non-surgical based treatment modalities have been consistently shown to produce optimal treatment outcomes in the vast majority of periodontitis patients.

**Conclusion**

This paper aimed to give an overview of the use of antibiotics in managing periodontal disease, but also how their abuse in the wider community has led to problems in terms of resistance. It is well recognised that the overuse of antibiotics has led to the development of resistant bacterial which have resulted in significant problems in the control of infectious diseases. It is of utmost importance that all healthcare professionals recognise the value of antibiotics and ensure that they are only used in appropriate situations; this equally applies to management of periodontitis which there are limited situations where there use can be justified.
References


1.